[PET in primary pulmonary or pleural cancer].

Abstract

In our hospital as in many others, primary lung cancer is the most frequent indication for FDG PET. Studies have assessed the clinical utility of this imaging modality in characterizing solitary pulmonary nodules or masses, initial staging, defining tumor volume in radiotherapy and searching for recurrence of or restaging non-small cell carcinoma; studies are currently underway to evaluate its use in early assessment of chemotherapy response. Small cell lung cancer has a high FDG uptake and PET/CT can be useful for rapid staging. False negative results may be due to pure bronchioloalveolar carcinomas and endocrine tumors. FDG-PET will certainly play a more important role in the diagnosis and follow-up of pleural cancers in the future. An unexpected positive FDG PET focus should be considered as a warning, but histological proof should precede any irrevocable decisions.

• Authors: Jean-Noël Talbot, Khaldoun Kerrou, Dany Grahek, Sona Balogova, Valérie Gounant, Armelle Lavole, Fabrice Gutman, Vanessa Aflalo-Hazan, Irena Raileanu, Françoise Montravers, Charles Mayaud
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 35 Issue 9 Pt 2 Pg. 1387-400 (Sep 2006) ISSN: 0755-4982 [Print] France
• Vernacular Title: La TEP dans les cancers bronchopulmonaires ou pleuraux primitifs.
• PMID: 16969335 (Publication Type: Journal Article, Review)

Chemical References

• Radiopharmaceuticals
• Fluorodeoxyglucose F18

Topics

• Diagnosis, Differential
• Fluorodeoxyglucose F18
• Humans
• Lung Neoplasms (diagnostic imaging)
• Neoplasm Staging
• Pleural Neoplasms (diagnostic imaging)
• Positron-Emission Tomography
• Radiopharmaceuticals